Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
about
How to Define the Latent Reservoir: Tools of the TradeBarriers to a cure for HIV in womenEpigenetic control of HIV-1 post integration latency: implications for therapyRedefining the viral reservoirs that prevent HIV-1 eradicationAnimal models in HIV cure researchPlasmacytoid dendritic cells of the gut: relevance to immunity and pathologyTranscriptional control of HIV latency: cellular signaling pathways, epigenetics, happenstance and the hope for a cureThe immunological synapse: the gateway to the HIV reservoirPersistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV modelUsing animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchImpact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infectionActivation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyEffects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized TrialReview: Influence of ART on HIV geneticsSwitching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNAIntensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infectedProfound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionThe Role of Caveolin 1 in HIV Infection and Pathogenesis.Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure.HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.CXCR4/IgG-expressing plasma cells are associated with human gastrointestinal tissue inflammation.Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism.Residual immune dysregulation syndrome in treated HIV infection.Immunity to HIV in Early LifeA comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cellsComparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers.Functional analyses reveal extensive RRE plasticity in primary HIV-1 sequences selected under selective pressureT-cell activation, both pre- and post-HAART levels, correlates with carotid artery stiffness over 6.5 years among HIV-infected women in the WIHSImmune activation and HIV persistence: implications for curative approaches to HIV infection.HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapyEffect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapyQuantifying the turnover of transcriptional subclasses of HIV-1-infected cellsReconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial.CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cellsAntiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.Finding a cure for HIV: will it ever be achievable?Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies
P2860
Q26766705-F5D0E138-1705-4AE7-90B3-901A61A490B6Q26768632-9DA92F0A-9466-4559-A85D-382C1A0FC177Q26781191-1A96E257-ECDE-4821-BD5B-2CA141C37799Q26827255-F60983C6-DAA0-4D92-B62D-EE110577CB8FQ26853069-1B9F3BDF-5C01-4628-AA9C-1392A684E488Q26864144-8A0E1137-92F2-4156-8669-61B228CFF712Q26999858-7BC06B6E-1CDA-40AD-B118-DD6B3725F1F1Q27002959-79C3743B-901D-41A7-9A0B-02DA14F1DC5AQ27335485-DAF89163-6572-4881-9DE8-A0EEDDDB4129Q28077662-AE8C5E81-66E0-470F-A6AC-389466AC65D3Q28481938-FFA9EFE4-D33E-49FC-9EFE-34850FCC19F9Q28544949-C44678A5-E1AE-4C2E-81CD-105675497146Q28552729-303CB817-C3BD-4486-96B6-39FA9D844049Q28649848-5A5B51AD-114D-4322-A617-9B037FF048A7Q28731610-00A37682-8CA0-41FC-AEB5-619A8BCFACE1Q28741704-2C99AAA7-E6C3-4530-A9AD-5E9BCB7DA18BQ28748901-0F057BD7-C098-4FA1-9EE7-D1090F480C2EQ32183747-FB7F5EBD-8D0E-45BA-8496-8783B3486965Q33460754-70FD7732-A6EB-4066-88DC-33328B611F15Q33593633-8FEDDF20-47F8-45C2-BF6A-CB6A0CBD3516Q33598231-32FCA005-EBDB-47AB-A1D9-1235EC2B23B4Q33693196-16533C76-963D-43B4-A48C-556375272807Q33798584-B6E86592-0CA7-414C-B365-53771C4E7840Q33889154-154B037A-75FC-4398-8153-E13CA74CB4C2Q34020121-A215470F-DFA8-42D2-8F10-6E42E5D33B03Q34033051-D73B259E-BDB4-4B10-8B7B-F0AE421063C4Q34033414-CE3BC792-98E2-4D6F-8343-9E3769D6E269Q34083315-65ED5237-F700-4570-B3C7-914145207CADQ34110556-46462BB0-25B1-4307-9ADF-C316F4F20F7AQ34342183-101A042E-AD43-429E-A124-B9AD0D1A7109Q34351320-A55BAB59-D916-4BA5-8AF0-5FDCDF6B7776Q34354110-D277959D-001B-47A0-9C1C-12904BA73614Q34384143-91F07284-9879-4A9A-9EE8-D85633979103Q34393716-3B23E57C-942A-42CB-97DA-CAB7CBC7D676Q34394987-FE580461-A464-4CB6-9B71-EE2D8B028A43Q34395160-4A3AFC75-8BA3-45AD-9685-3843EE2BD7CDQ34539993-A9B5C769-C12E-4871-A3B5-0EFAB251FAF1Q34567084-FD31D2F2-F0B9-4522-8FDC-93EDBA35D471Q34575989-E04289F9-41FF-45CC-96B8-3CD2B66DCE8FQ34607763-759D52D7-531F-4C9F-B434-FB98F505F751
P2860
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Differences in HIV burden and ...... ressive antiretroviral therapy
@ast
Differences in HIV burden and ...... ressive antiretroviral therapy
@en
Differences in HIV burden and ...... ressive antiretroviral therapy
@nl
type
label
Differences in HIV burden and ...... ressive antiretroviral therapy
@ast
Differences in HIV burden and ...... ressive antiretroviral therapy
@en
Differences in HIV burden and ...... ressive antiretroviral therapy
@nl
prefLabel
Differences in HIV burden and ...... ressive antiretroviral therapy
@ast
Differences in HIV burden and ...... ressive antiretroviral therapy
@en
Differences in HIV burden and ...... ressive antiretroviral therapy
@nl
P2093
P2860
P356
P1476
Differences in HIV burden and ...... ressive antiretroviral therapy
@en
P2093
Alex L M Choi
Amandeep K Shergill
Ashley T Haase
C Bradley Hare
Elizabeth Sinclair
Harry Lampiris
Joseph K Wong
Katsuya Fujimoto
Kenneth McQuaid
Lijie Duan
P2860
P304
P356
10.1086/656722
P407
P577
2010-10-12T00:00:00Z